Get the Daily Brief
Latest Biotech News
Regulatory approvals – lipid management
Merck received FDA approval for Lipfendra, the first oral PCSK9 inhibitor, expanding the cholesterol-lowering toolkit beyond injectable agents. The macrocyclic peptide is designed for oral...
Oncology – targeted therapy regulatory greenlights
The FDA approved gedatolisib (Revtorpyk) plus fulvestrant, with or without palbociclib, for hormone receptor–positive, HER2-negative advanced breast cancer without a PIK3CA mutation after...
Immuno-oncology research – dosing timing and outcomes
A British Journal of Cancer analysis reported that the timing of immune checkpoint inhibitor dosing can be associated with meaningful differences in overall survival for patients with advanced...
Cancer immunology – prevention strategy in early pancreatic lesions
Researchers at Johns Hopkins University reported early clinical proof-of-concept for a peptide-based pancreatic cancer vaccine targeting the six most common mutant KRAS variants. In a Cancer...
Neuropsychiatry – M&A and late-stage pipeline expansion
Eli Lilly agreed to acquire AtaiBeckley in a deal valued at up to $3.8 billion to broaden its neuroscience and mental health portfolio. The transaction adds AtaiBeckley’s BPL-003 (mebufotenin...
Cell therapy – manufacturing scale-up toward GMP
Cell therapy manufacturing is shifting from academic development to GMP-ready workflows, with a focus on scalability and regulatory comparability. A report highlighted how early adoption of closed...
Companion diagnostics – germline and somatic testing integration
An executive Q&A from Labcorp Oncology underscored the growing operational and clinical importance of pairing germline and somatic testing in oncology. Rebecca Previs and Sarah Young discussed how...
Early-stage platform – gene therapy for inherited night blindness
A preclinical study in Gene Therapy reported that gene augmentation therapy reversed complete congenital stationary night blindness in mice, restoring more reliable visual responses. The work...
Inflammaging biology – macrophage EP2 signaling and organ aging
Stanford-affiliated researchers linked organ aging to impaired clearance of senescent neutrophils and identified a key signaling axis involving tissue-resident macrophages and EP2. The study,...
Cardio-metabolic risk – dosing risk controls excluded (non-oncology filtered out)
No additional high-impact, biotech-industry–specific regulatory, clinical, or commercial stories remained after filtering the provided list down to events directly relevant to biotech...
Regulatory approval: first-in-class oral PCSK9 therapy
The FDA approved Lipfendra (oral PCSK9 inhibitor) as the first pill option in the PCSK9 inhibitor class, expanding cholesterol-lowering beyond injectable peptide therapy. Merck’s macrocyclic...
Big deal in mental health: Lilly acquires AtaiBeckley
Eli Lilly agreed to acquire AtaiBeckley in a deal valued at up to $3.8 billion, aiming to expand its neuroscience portfolio with AtaiBeckley’s late-stage pipeline. Analysts cited Eli Lilly’s...
Oncology regulatory and efficacy signals: PI3K/AKT/mTOR in HR+/HER2− breast cancer
The FDA approved gedatolisib (Revtorpyk) plus fulvestrant, with or without palbociclib, for PIK3CA wild-type hormone receptor–positive, HER2-negative advanced breast cancer after progression on...
Clinical evidence reanalysis: timing of immune checkpoint inhibitor dosing
A British Journal of Cancer analysis suggests that the timing of immune checkpoint inhibitor administration can influence survival in advanced cancer. Using a large, single-centre cohort,...
Early-stage pipeline strategy: OPTIM trial escalates treatment after nivolumab
Researchers launched and reported on OPTIM, a randomized Phase II strategy in recurrent or metastatic squamous cell carcinoma of the head and neck that escalates therapy based on early results....
Platform biology: EP2 blockade preserves macrophage clearance and slows organ aging
A Science paper from Stanford Medicine researchers linked organ aging to breakdown in tissue-resident macrophage clearance of senescent neutrophils. The group reported that advancing age impairs...
Public policy and access: Medicare GLP-1 Bridge lowers monthly prices for selected drugs
The Trump administration launched the Medicare GLP-1 Bridge program, setting the cost for three weight-loss medications at $50 per month: Wegovy, a KwikPen version of Zepbound (tirzepatide), and...
Translational imaging and care: AI glaucoma prognosis with $3.7 million NIH grant
The National Eye Institute awarded Mingquan Lin, PhD, a five-year $3.7 million NIH grant to develop AI for primary open-angle glaucoma prognosis. The work, led through the University of Minnesota...
Study design signal: oral feeding assessment using noninvasive acoustics in preterm infants with BPD
A new approach described in a preclinical/clinical study uses noninvasive acoustic assessment to measure feeding skills in preterm infants with bronchopulmonary dysplasia (BPD). The work targets a...
Gene therapy preclinical proof: restores congenital night blindness in mice
A Gene Therapy journal preclinical study reported that gene augmentation reversed complete congenital stationary night blindness in mouse models. The work targeted complete cCSNB, a condition...